company background image
EVL logo

Evolus DB:EVL Stock Report

Last Price

€14.70

Market Cap

€982.3m

7D

-3.3%

1Y

83.8%

Updated

07 Nov, 2024

Data

Company Financials +

EVL Stock Overview

A performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.

EVL fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Evolus, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evolus
Historical stock prices
Current Share PriceUS$14.70
52 Week HighUS$15.90
52 Week LowUS$7.40
Beta1.31
11 Month Change-0.68%
3 Month Change24.58%
1 Year Change83.75%
33 Year Change126.15%
5 Year Change13.95%
Change since IPO59.26%

Recent News & Updates

Recent updates

Shareholder Returns

EVLDE PharmaceuticalsDE Market
7D-3.3%-0.8%1.1%
1Y83.8%-16.7%12.5%

Return vs Industry: EVL exceeded the German Pharmaceuticals industry which returned -15.7% over the past year.

Return vs Market: EVL exceeded the German Market which returned 11.8% over the past year.

Price Volatility

Is EVL's price volatile compared to industry and market?
EVL volatility
EVL Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement7.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: EVL has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: EVL's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012304David Moatazediwww.evolus.com

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names.

Evolus, Inc. Fundamentals Summary

How do Evolus's earnings and revenue compare to its market cap?
EVL fundamental statistics
Market cap€982.34m
Earnings (TTM)-€51.37m
Revenue (TTM)€230.00m

3.6x

P/S Ratio

-16.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVL income statement (TTM)
RevenueUS$248.33m
Cost of RevenueUS$74.64m
Gross ProfitUS$173.69m
Other ExpensesUS$229.15m
Earnings-US$55.46m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.88
Gross Margin69.94%
Net Profit Margin-22.33%
Debt/Equity Ratio2,057.9%

How did EVL perform over the long term?

See historical performance and comparison